Oncoinvent publishes corporate presentation on Radspherin alpha therapy for peritoneal metastases

• Oncoinvent highlighted Radspherin, a radium-224 alpha therapy delivered into the peritoneum via catheter 1-3 days post-surgery.
• Ovarian cancer Phase 1: 90% remained without peritoneal recurrence at 24 months at the 7 MBq recommended dose.
• Colorectal cancer Phase 1/2a: 72% remained without peritoneal recurrence at 18 months at 7 MBq; peritoneal recurrence 28% versus ~50% literature benchmark.
• Safety update across 68 patients: no dose-limiting toxicity; three serious adverse events deemed possibly related, including bowel perforation and obstruction.
• Development plan targets a 2030 submission; Phase 3 planned in primary ovarian cancer, Phase 2 and Phase 2/1 programs also outlined.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoinvent ASA published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.